CRAFTED. cover image

CRAFTED.

AI, Psychedelics, the Gut-Brain Axis, and New Frontiers in BioTech | From SXSW's Next Stage (Re-release)

Feb 27, 2025
In this insightful discussion, Amy Kruse, a neuroscientist and Chief Investment Officer at Satori Neuro, and Matias Serebrinsky, co-founder of PsyMed Ventures, delve into the transformative role of AI and biotechnology in mental health. They explore the hype around psychedelics and emphasize the significance of the gut-brain axis. The duo also highlights the evolution of neurotechnology and the potential for innovative treatments, alongside the challenges of funding health tech startups, particularly focusing on mental wellness and women's health.
42:33

Podcast summary created with Snipd AI

Quick takeaways

  • Advancements in neurotechnology and AI are revolutionizing mental health treatment by integrating biomarker data for personalized therapeutic interventions.
  • While psychedelics show promise for certain mental health disorders, their widespread promotion raises concerns about safety and efficacy.

Deep dives

Advancements in Neurotechnology

Neurotechnology has made significant strides, enabling the development of brain implants that allow humans to control robotic arms through thought alone. This progress reflects an intersection of software, hardware, and biotechnology that is transforming mental health and wellness. With the advent of microelectronic circuits, the ability to compute directly within the human brain has become a reality, aligning with Moore's Law. These advancements open new avenues for treating neurological disorders and understanding brain functionality.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner